

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 February 2020 (06.02.2020)



(10) International Publication Number
WO 2020/025672 A1

(51) International Patent Classification:

C07K 16/36 (2006.01) C07K 16/46 (2006.01)
C07K 16/40 (2006.01) A61P 7/04 (2006.01)

(21) International Application Number:

PCT/EP2019/070628

(22) International Filing Date:

31 July 2019 (31.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2018/097834

01 August 2018 (01.08.2018) CN

PCT/CN2018/099339

08 August 2018 (08.08.2018) CN

18193191.6 07 September 2018 (07.09.2018) EP

(71) Applicant: NOVO NORDISK A/S [DK/DK]; Novo Allé,
2880 Bagsværd (DK).

(72) Inventors: THORN, Karina; Novo Allé, 2880 Bagsværd (DK). HANSEN, Bjarne, Gram; Novo Allé, 2880 Bagsværd (DK). JOHNSSEN, Laust, Bruun; Novo Allé, 2880 Bagsværd (DK). HARNDAAHL, Mikkel, Nors; Novo Allé, 2880 Bagsværd (DK). YANG, Zhiru; Beijing Novo Nordisk Pharmaceuticals Sci & Tech Co. Ltd Building #2/#4, Bio-tech R&D Center, No.20 Life Science Park Road, Beijing, Changping District 102206 (CN). ØSTERGAARD, Henrik; Novo Allé, 2880 Bagsværd (DK). GREISEN, Per, J; Novo Allé, 2880 Bagsværd (DK). JOHANSSON, Eva; Novo Allé, 2880 Bagsværd (DK). RASCH, Morten, Grønbech; Novo Allé, 2880 Bagsværd (DK). CHEN, Jianhe; Beijing Novo Nordisk Pharmaceuticals Sci & Tech Co. Ltd Building #2/#4, Bio-tech R&D Center, No.20 Life Science Park Road, Beijing, Changping District 102206 (CN). SVENSSON, Anders; Novo Allé, 2880 Bagsværd (DK). ZHU, Haisun; Beijing Novo Nordisk Pharmaceuticals Sci & Tech Co. Ltd Building #2/#4, Bio-tech R&D Center, No.20 Life Science Park Road, Beijing, Changping District 102206 (CN). ZHOU, Rong; Beijing Novo Nordisk Pharmaceuticals Sci & Tech Co. Ltd Building #2/#4, Bio-tech R&D Center, No.20 Life Science Park Road, Beijing, Changping District 102206 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IMPROVED PROCOAGULANT ANTIBODIES

(57) Abstract: The present invention relates to multispecific procoagulant antibodies capable of binding to coagulation Factor IX (FIX) and/or the activated form thereof Factor IXa (FIXa), and Factor X (FX) and/or the activated form thereof Factor Xa (FXa) and promoting FX activation by FIXa, antibodies binding their epitopes or parts thereof and methods and composition for treating subjects suffering from a coagulopathy such as haemophilia A as well as kits, methods of manufacture and methods of use.

WO 2020/025672 A1